CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Evaluating Multimodal Functionality of Chimeric Antigen Receptor T Cells at Single-Cell Resolution through Optofluidics Analysis.
Evaluating Multimodal Functionality of Chimeric Antigen Receptor T Cells at Single-Cell Resolution through Optofluidics Analysis.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
过继性 T 细胞疗法是一种新型治疗模式:先对患者自体 T 细胞进行基因改造,使其表达靶向肿瘤的嵌合抗原受体(CAR),再于体外扩增并回输患者体内。尽管该疗法在晚期血液系统恶性肿瘤患者中显示出显著抗肿瘤效力,仍有相当一部分患者未能获得持久应答。临床结局差异可能由多种个体因素导致,越来越多证据表明,输注前 CAR-T 产品中多功能 T 细胞所占比例与癌症缓解持久性密切相关。然而,目前 CAR-T 产品的常规评估依赖群体平均测量或终点检测,限制了对功能更强的细胞亚群进行分离和研究。本研究展示了一套工作流程,利用光流控平台评估单个 CAR-T 细胞的细胞因子分泌谱及 CD137 表达所反映的活化状态,并可选择加入细胞毒活性评估。多模式功能最强的细胞可被分离用于进一步分析,从而为下一代 CAR-T 细胞疗法设计提供依据。
Adoptive T-cell therapy is a novel treatment paradigm in which autologous T cells are genetically modified to express a tumor-targeting chimeric antigen receptor (CAR) prior to ex vivo expansion and re-infusion into the patient. Despite remarkable demonstrations of anti-tumor potency in patients with advanced hematological malignancies, long-lasting responses fail to manifest in a substantial fraction of cases.
Although several idiosyncratic factors may contribute to the variability in clinical outcomes, there is mounting evidence that the percentage of polyfunctional T cells in the pre-infusion CAR-T cell product strongly correlates with the durability of cancer remission. Unfortunately, standard evaluations of CAR-T cell products currently rely on bulk population measurements or terminal assays, limiting the ability to isolate and study sub-populations with heightened functional properties.
Here, we demonstrate a workflow that leverages an optofluidics platform to evaluate both the cytokine secretion profile and activation via CD137 expression of individual CAR-T cells, which can be optionally combined with cytotoxic activity assessment. Cells exhibiting the greatest degree of multimodal functionality can be isolated for further analyses to inform the design of next-generation CAR-T cell therapies.
MEMBER ACCOUNT
登录成功会直接打开下一页。